Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer.

Literature DB >> 23817686

PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer.

Ali Afshar-Oromieh¹, Uwe Haberkorn, Boris Hadaschik, Gregor Habl, Matthias Eder, Michael Eisenhut, Heinz-Peter Schlemmer, Matthias C Roethke.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2013 PMID： 23817686 DOI： 10.1007/s00259-013-2489-5

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

4 in total

1. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

Authors: A Afshar-Oromieh; U Haberkorn; M Eder; M Eisenhut; C M Zechmann
Journal: Eur J Nucl Med Mol Imaging Date: 2012-02-04 Impact factor: 9.236

2. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

Authors: Matthias Eder; Martin Schäfer; Ulrike Bauder-Wüst; William-Edmund Hull; Carmen Wängler; Walter Mier; Uwe Haberkorn; Michael Eisenhut
Journal: Bioconjug Chem Date: 2012-03-13 Impact factor: 4.774

3. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236

4. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.

Authors: John A Barrett; R Edward Coleman; Stanley J Goldsmith; Shankar Vallabhajosula; Neil A Petry; Steve Cho; Thomas Armor; James B Stubbs; Kevin P Maresca; Michael G Stabin; John L Joyal; William C Eckelman; John W Babich
Journal: J Nucl Med Date: 2013-01-09 Impact factor: 10.057

4 in total

29 in total

1. [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors: Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal: J Med Chem Date: 2015-12-16 Impact factor: 7.446

2. (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Authors: Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal: Eur J Nucl Med Mol Imaging Date: 2016-03 Impact factor: 9.236

3. Preliminary results on response assessment using ⁶⁸Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.

Authors: Anna Katharina Seitz; Isabel Rauscher; Bernhard Haller; Markus Krönke; Sophia Luther; Matthias M Heck; Thomas Horn; Jürgen E Gschwend; Markus Schwaiger; Matthias Eiber; Tobias Maurer
Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-28 Impact factor: 9.236

Review 4. Current use of PSMA-PET in prostate cancer management.

Authors: Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal: Nat Rev Urol Date: 2016-02-23 Impact factor: 14.432

Review 5. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors: Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal: Eur J Nucl Med Mol Imaging Date: 2017-04-14 Impact factor: 9.236

PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer.

1. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

2. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

3. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

4. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.

1. [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

2. (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

3. Preliminary results on response assessment using ⁶⁸Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.

Review 4. Current use of PSMA-PET in prostate cancer management.

Review 5. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

6. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.

7. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.

8. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

Review 9. Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.

10. Magnetic resonance molecular imaging for non-invasive precision cancer diagnosis.